Want to join the conversation?
$MRK said the European Commission has approved KEYTRUDA based on findings from KEYNOTE-010 study. KEYTRUDA is an anti-PD-1 therapy for patients with locally advanced or metastatic non-small cell lung cancer in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?